Comparison of two dosing regimens of Alefacept in subjects weighing between 100kg and 150kg with moderate to severe Chronic Plaque Psoriasis

Inclusion Criteria:

• Body weight between 100kg and 150kg
• Diagnosis of Chronic Plaque Psoriasis with Body Surface Area (BSA) involvement of ≥ 10%
• Candidate for phototherapy or systemic therapy for Psoriasis
• CD4 + T lymphocyte counts > lower limit of normal

Exclusion Criteria:

• Clinically significant abnormal hematology values or blood chemistry values
• ALT or AST value of ≥ 3x the upper limit of normal
• Other types of Psoriasis
• Serious infection within 3 months prior to 1st dose of study drug
• Antibody positive for HIV
• History of malignancy
• History of severe allergic or anaphylactic reactions
• History of any clinically significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, neurologic, dermatologic, psychiatric, renal and/or other major disease